Drug intelligence / Profile preview

ABSK051

Development stage: Unknown
Lead developer: Abbisko Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ABSK051 is a potent, small molecule inhibitor of CD73 (ecto-5'-nucleotidase) developed by Abbisko Therapeutics. CD73 is an enzyme that catalyzes the conversion of adenosine monophosphate (AMP) to adenosine, which acts as a potent immunosuppressive molecule within the tumor microenvironment. By inhibiting CD73, ABSK051 aims to decrease adenosine accumulation, thereby reversing immune suppression and promoting an anti-tumor immune response. The drug is currently undergoing Phase 1 clinical evaluation for patients with advanced solid tumors, exploring its safety, tolerability, and preliminary efficacy as both a monotherapy and in combination with other therapeutic agents.

Targets

NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on ABSK051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABSK051.

Explore the full profile